- Home
- MLYS vs ORIC Comparison
MLYS vs ORIC Comparison
Compare MLYS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- ORIC
- Stock Information
- Founded
- MLYS 2019
- ORIC 2014
- Country
- MLYS United States
- ORIC United States
- Employees
- MLYS N/A
- ORIC N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- ORIC Health Care
- Exchange
- MLYS Nasdaq
- ORIC Nasdaq
- Market Cap
- MLYS 590.3M
- ORIC 633.7M
- IPO Year
- MLYS 2023
- ORIC 2020
- Fundamental
- Price
- MLYS $11.87
- ORIC $9.12
- Analyst Decision
- MLYS Strong Buy
- ORIC Strong Buy
- Analyst Count
- MLYS 2
- ORIC 9
- Target Price
- MLYS $30.00
- ORIC $18.75
- AVG Volume (30 Days)
- MLYS 255.3K
- ORIC 482.7K
- Earning Date
- MLYS 11-11-2024
- ORIC 11-12-2024
- Dividend Yield
- MLYS N/A
- ORIC N/A
- EPS Growth
- MLYS N/A
- ORIC N/A
- EPS
- MLYS N/A
- ORIC N/A
- Revenue
- MLYS N/A
- ORIC N/A
- Revenue This Year
- MLYS N/A
- ORIC N/A
- Revenue Next Year
- MLYS N/A
- ORIC N/A
- P/E Ratio
- MLYS N/A
- ORIC N/A
- Revenue Growth
- MLYS N/A
- ORIC N/A
- 52 Week Low
- MLYS $6.06
- ORIC $6.33
- 52 Week High
- MLYS $16.91
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- MLYS 41.32
- ORIC 46.99
- Support Level
- MLYS $11.30
- ORIC $8.11
- Resistance Level
- MLYS $13.06
- ORIC $8.90
- Average True Range (ATR)
- MLYS 1.01
- ORIC 0.74
- MACD
- MLYS -0.22
- ORIC -0.09
- Stochastic Oscillator
- MLYS 14.43
- ORIC 33.78
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.